Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Centessa Pharmaceuticals stock last closed at $39.42, down 0.08% from the previous day, and has increased 187.53% in one year. It has overperformed other stocks in the Biotechnology industry by 2 percentage points. Centessa Pharmaceuticals stock is currently +260% from its 52-week low of $10.95, and -2.06% from its 52-week high of $40.25.
At the moment, there are 154.57M CNTA shares outstanding. The market value of CNTA is $6.09B. In the past 24 hours, 2.97M CNTA shares were traded.
How to Buy Centessa Pharmaceuticals Stock
Not sure how to invest in Centessa Pharmaceuticals stock? Here's how.
Figure out where to buy Centessa Pharmaceuticals stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Centessa Pharmaceuticals stock.
Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Put funds into your investment account: Choose your payment method and add your info.
Analyze Centessa Pharmaceuticals stock: The Centessa Pharmaceuticals ticker symbol is CNTA. Is Centessa Pharmaceuticals stock a good investment? Should you buy shares of CNTA? How do CNTA's underlying business fundamentals look? Do top analysts think Centessa Pharmaceuticals is a good buy? Why has CNTA's stock price moved recently? (Hint: Our stock market research website can help you evaluate if CNTA is a good stock to buy).
Place your CNTA buy order: Decide if you will purchase CNTA shares at the current market price or use a limit order to purchase CNTA shares at a particular price.
Keep an eye on your CNTA investment: Create a watchlist to key updates about your new investment in Centessa Pharmaceuticals stock.
Step 1: Figure out where to buy Centessa Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy CNTA shares.
A brokerage account allows you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to global financial markets: From Tech to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal information so you can buy CNTA today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Centessa Pharmaceuticals stock
After you have identified the best place to buy Centessa Pharmaceuticals stock, it's crucial to evaluate their stock before you invest, so you can wrap your head around the risk and opportunity.
Centessa Pharmaceuticals stock quick numbers
CNTA Price
$39.42
1w %
-0.03%
1y %
187.53%
5y %
N/A
P/E
-27x
P/B
11.56x
P/S
355.14x
PEG
N/A
Revenue
$15.00M
Earnings
-$197.53M
Fore. Rev. Growth
109.37%
Fore. Earn. Growth
N/A
Market Cap
$6.09B
Next Earnings
May 18, 2026
Next Dividend
N/A
Centessa Pharmaceuticals Due Diligence Score
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis.
CNTA has cash burn of 194188000. It has sufficient cash and short-term investments to cover this for at least one year.
CNTA has $294.58M in cash and short term investments. This is sufficient to cover its annual cash burn of $194.19M.
Total CNTA debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than long-term liabilities on the CNTA balance sheet.
There are more short-term assets than short-term liabilities on the CNTA balance sheet.
Signs that CNTA is not financially healthy:
CNTA profit margin has gone down from N/A to -1,316.9% in the past year.
Is it a good time to buy Centessa Pharmaceuticals stock, according to Wall Street analysts?
Out of 7 Wall Street analysts who track CNTA, the consensus analyst rating on CNTA is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Latest CNTA Analyst Upgrades/Downgrades
Mayank Mamtani, a top 3% analyst from B. Riley Securities maintains CNTA with a strong buy rating and raises their CNTA price target from $33.00 to $42.00, on Dec 1, 2025.
B. Riley Securities's Mayank Mamtani raised their price target on Centessa Pharmaceuticals (NASDAQ: CNTA) by 27.3% from $33 to $42 on 2025/12/01. The analyst maintained their Strong Buy rating on the stock.
Mamtani said they hiked their Centessa Pharmaceuticals price target on the belief that Phase 2 CRYSTAL-1 data positions ORX750 as "significantly de-risked for potential first-in-class status" in narcolepsy type 2 and idiopathic hypersomnia.
The analyst explained that ORX750 achieved over 20 minutes of placebo-adjusted improvement on the Maintenance of Wakefulness Test, matching TAK-861 and Alkermes' alixorexton at 5x to 15x lower doses.
Debjit Chattopadhyay, a top 14% analyst from Guggenheim maintains CNTA with a strong buy rating and raises their CNTA price target from $28.00 to $43.00, on Nov 18, 2025.
Last year, CNTA revenue was $15.00M. In the past two year, CNTA's revenue has gone up by 47.95% per year. This was faster than the Biotechnology industry average of 27.16%.
No, Centessa Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your CNTA buy order
You have two main options:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are mostly fine.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a particular price limit, use a limit order.
Press the Open button and eToro will place your order.
If you require additional info about buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Centessa Pharmaceuticals share?
As of Apr 30, 2026, it costs $39.42 to buy one share of Centessa Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.254 shares of CNTA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.